Latest Clinuvel Pharmaceuticals (ASX:CUV) News

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.

The FDA has removed the postmarketing cardiac repolarization study requirement for Clinuvel's SCENESSE®, reflecting confidence in its long-term safety profile. This marks a regulatory milestone for the only approved treatment for erythropoietic protoporphyria in the US.

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.

CLINUVEL Pharmaceuticals has received final scientific advice from the European Medicines Agency on the design of its pivotal Phase III trial for SCENESSE in vitiligo, endorsing a comprehensive evidence approach and prioritising patients with darker skin tones.

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.

CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.

Clinuvel Pharmaceuticals has initiated dosing in a preclinical study of its novel controlled-release injectable peptide platform, VLRX-L, aiming to enhance drug delivery for melanocortin-based therapies. Preliminary results are expected in the second half of 2026.

CLINUVEL Pharmaceuticals is significantly expanding its VALLAURIX RD&I Centre in Singapore with a five-year strategic investment, aiming to become a global leader in advanced peptide drug delivery.

Health Canada has requested additional information, extending its review of CLINUVEL’s SCENESSE® for erythropoietic protoporphyria (EPP) into 2026. Meanwhile, Canadian patients continue to access the treatment via a Special Access Program.

The European Medicines Agency has approved continuous bi-monthly dosing of CLINUVEL’s SCENESSE® for adult erythropoietic protoporphyria patients, removing previous annual dose limits and aligning Europe with US treatment standards.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.